In a CKD mouse model, FGF23 signaling inhibition improved anemia and iron deficiency by increasing EPO levels, hemoglobin, red blood cells, bone marrow erythroid progenitors, and driving hematopoietic stem cells to the erythroid lineage [62]. The gene discussed is EPO; the disease is chronic kidney disease.